Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing XZP-3621 to crizotinib in non-small cell lung cancer is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• XZP-3621

Snippet

Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN